Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

PBE vs. SHPAX: which is better?

Bottom line

PBE vs SHPAX: the short answer

PBE (Invesco Biotechnology & Genome ETF) and SHPAX (Health & Biotechnology Portfolio) are quite different portfolios: only about 26% of their top holdings (by weight) are shared.

PBE is cheaper at 0.59% vs 3% — a difference of $241 a year per $10,000 invested.

Over five years, PBE returned +3.4% a year vs +3.1% for SHPAX (reporting dates differ).

SHPAX has a front-end sales load of up to 5.75%; the other does not.

Updated Nov 19, 2026

PBE vs SHPAX side by side

PBESHPAX
TypeETFMutual fund
Fund familyInvescoSaratoga Advantage
CategoryTechnology SectorTechnology Sector
Expense ratio0.59%3%
Annual cost per $10k$59$300
10-yr cost on $10k (prospectus)$738$3,702
Max front loadNone5.75%
12b-1 fee——
1-yr return+24.7%−5.5%
5-yr return (annualized)+3.4%+3.1%
10-yr return (annualized)+5.2%+4.1%
Best quarter+25.3%+15.0%
Worst quarter−24.3%−13.0%
Net assets (fund)$281.9M$10.5M
Number of holdings3329
Portfolio turnover103%22%
Returns as ofDec 31, 2025Dec 31, 2024

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearPBESHPAXDifference
2024+1.1%+0.3%+0.8%
2023+3.7%−0.4%+4.0%
2022−10.8%+2.0%−12.8%
2021+1.6%+16.7%−15.1%
2020+25.5%+3.6%+21.9%
2019+18.3%+16.2%+2.1%
2018+0.2%−5.5%+5.7%
2017+22.4%+12.0%+10.5%
2016−23.0%−2.0%−21.1%
2015+2.0%+6.9%−4.9%

Source: Fund prospectus bar charts

Holdings overlap

7 of PBE's top 25 holdings also appear in SHPAX's top 25.

Shared top holdings
HoldingPBESHPAX
Regeneron Pharmaceuticals, Inc.5.47%3.93%
Amgen Inc.5.22%5.04%
Vertex Pharmaceuticals Inc.4.99%3.36%
Gilead Sciences, Inc.4.43%3.94%
United Therapeutics Corp.4.08%6.17%
Incyte Corp.3.06%2.89%
Exelixis, Inc.2.64%4.55%

Source: SEC Form N-PORT

PBE top 10

  1. Invesco Private Prime Fund — 12.89%
  2. Regeneron Pharmaceuticals, Inc. — 5.47%
  3. Amgen Inc. — 5.22%
  4. CareDx, Inc. — 5.04%
  5. Vertex Pharmaceuticals Inc. — 4.99%
  6. Invesco Private Government Fund — 4.97%
  7. Royalty Pharma PLC — 4.94%
  8. Biogen Inc. — 4.79%
  9. Gilead Sciences, Inc. — 4.43%
  10. United Therapeutics Corp. — 4.08%

SHPAX top 10

  1. Cardinal Health Inc — 6.44%
  2. Jazz Pharmaceuticals Plc — 6.19%
  3. United Therapeutics Corp — 6.17%
  4. Amgen Inc — 5.04%
  5. Mckesson Corp — 4.90%
  6. Lantheus Holdings Inc — 4.64%
  7. Exelixis Inc — 4.55%
  8. Novartis Ag — 4.50%
  9. Cencora Inc — 4.33%
  10. Gilead Sciences Inc — 3.94%

FAQ

What is the difference between PBE and SHPAX?
PBE (Invesco Biotechnology & Genome ETF) and SHPAX (Health & Biotechnology Portfolio) are quite different portfolios: only about 26% of their top holdings (by weight) are shared. PBE is cheaper at 0.59% vs 3% — a difference of $241 a year per $10,000 invested.
Which is cheaper, PBE or SHPAX?
PBE has the lower expense ratio (0.59%).
Should I own both PBE and SHPAX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.